Comparison of Glucagon-Like-Peptide-1 (GLP-1) Receptor PET/CT, SPECT/CT and 3T MRI for the Localisation of Insulinomas: Evaluation of Accuracy in a Prospective Crossover Imaging Study Abstract #2003

Introduction: Benign insulinomas are the most prevalent cause of endogenous hyperinsulinaemic hypoglycaemia (EHH) in adults and due to their small size difficult to localise.
Aim(s): We aimed at prospectively comparing the accuracy and clinical impact of glucagon-like-peptide-1 receptor (GLP1-R) PET/CT, SPECT/CT, standardised 3-Tesla contrast-enhanced (ce)MRI and non-standardised baseline imaging (ceCT/ceMRI) in patients with EHH.
Materials and methods: We prospectively enrolled patients with neuroglycopenic symptoms due to EHH and no evidence for metastatic disease on conventional imaging. Standardised ceMRI was performed using clinical routine sequences. SPECT/CT was performed 4h/72h after injection of 111In-DOTA-exendin-4 and PET/CT 2,5h after injection of 68Ga-DOTA-exendin-4 in a randomized, cross over design. The reference standard was surgery with histology and normalisation of blood glucose levels within 10 days.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr. Antwi Antwi

To read results and conclusion, please login ...

Further abstracts you may be interested in

#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#83 Surgical treatment of duodenopancreatic neuroendocrine tumors (pNETs) in patients with multiple endocrine neoplasia type 1 (MEN 1): a Dutch consensus statement
Introduction: Duodenopancreatic neuroendocrine tumors (pNETs) in multiple endocrine neoplasia type 1 (MEN 1) are the most important cause of MEN 1-related death. Surgery is the only curative treatment, but controversy exists on the optimal strategy. Recent guidelines on pNETs have limited recommendations specific for MEN 1. Therefore, a Dutch multidisciplinary consensus meeting was organized.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Carolina RC Pieterman
#194 Pancreatic Neuroendocrine Tumors: Experience of Endocrinology Department of the University Hospital of Coimbra
Introduction: Pancreatic neuroendocrine tumors (PNETs) are uncommon neoplasms, comprising 1-2% of all pancreatic tumors. The majority are nonfunctional. Of the functional tumors, insulinomas are the most common.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Alexandra Vieira
Authors: Vieira A, Santos J, Gomes L, Moreira A, ...
#221 Diagnostic Algorithm of Pancreatic Neuroendocrine Tumors
Introduction: Diagnostics of pNETs is associated with certain problems due to a variety of clinical features, including a rather small size of primaries and, quite often, multiple lesions.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ivan A Vasiliev
#348 Management of Multiple Endocrine Neoplasia Type 1 in Patients with Pancreatic Neuroendocrine Tumors
Introduction: Screening for MEN-1 is an integral part of examination of patients with pNETs because revelation of this hereditary pathology radically influences tactics of treatment.
Conference:
Category: Basic
Presenting Author: Ivan Vasiliev